Abstract
Background The present study aimed to assess the efficacy of a new haplo-paraspinal-muscle-preserving (HMP) laminoplasty technique in the treatment of cervical myelopathy.
Methods The medical records of 68 patients diagnosed with multisegmental cervical myelopathy were retrospectively reviewed. Of these, 22 patients who underwent HMP laminoplasty were defined as the muscle-preserved group (MP), and 46 patients who underwent traditional open-door laminoplasty were enrolled and defined as the traditional open-door laminoplasty group (LP). Patient demographic data and surgical parameters like clinical and radiological parameters, operation duration, blood loss, and spinal canal expansion distance were compared.
Results Average surgical time and blood loss were significantly reduced in the MP group when compared with the LP group (P < 0.05). Both groups demonstrated significant improvements in neurological function and spinal canal expansion (P > 0.05). However, the visual analog scale score in the MP group was significantly lower compared with the LP group at the 6-month follow-up (P < 0.05), but no differences were found at the 1-year follow-up. The loss of lordosis was more prominent in the LP group when compared with the MP group at 1-year follow-up (P < 0.05). Lower events of persistent axial pain were found in the MP group but with no statistical significance. More hinge side laminae fractures could be found in the MP group, but more hinge side displacements were found in the LP group.
Conclusions The HMP laminoplasty technique is relatively safe, effective, easier to perform, and better for lordosis maintenance and complication control compared with the traditional open-door technique.
Clinical Relevance Although traditional open-door laminoplasty is an efficient approach in treating multisegmental cervical myelopathy, the complications could significantly affect the clinical outcome. Our new HMP laminoplasty technique has a lower complication rate and a better lordosis maintenance ability; therefore, it could be a better choice in treating multisegmental cervical myelopathy.
Level of Evidence 3.
Footnotes
Funding This research was supported by grants from the National Natural Science Foundation of China (82172470, 81972090, 81772376, 82072471), Shanghai Science & Technology Commission Rising-Star Program (20QA1409200), Biopharmaceutical Science and Technology Supporting Foundation (21S31901400), Shanghai Shenkang Hospital Development Center Clinical Innovation Project (SHDC2020CR6018), Shanghai Changzheng Hospital Medical Service Innovation Project (2020CZWJFW15), and High-Quality Research Cultivating Project (2020YCGPZ-207).
Declaration of Conflicting Interests The authors report no conflicts of interest in this work.
Ethics Approval This retrospective study was approved by the ethics committee and the Institutional Review Board (IRB) of Naval Medical University (IRB number: 2021SL044). Written informed consent was obtained from all participants.
Authors’ Contributions Study conception and design: X.S., C.X., Y.L., R.W., Z.Z.; Acquisition, analysis, and/or interpretation of data: X.S., C.X., R.W., Z.Z., M.Q., Y.Z., Y.L., H.W.; Drafting/revision of the work for intellectual content and context: Y.L., C.X., X.S., W.Y.; Final approval and overall responsibility for the published work: Y.L., W.Y. All authors read and approved the final manuscript.
- This manuscript is generously published free of charge by ISASS, the International Society for the Advancement of Spine Surgery. Copyright © 2023 ISASS. To see more or order reprints or permissions, see http://ijssurgery.com.